Nuclease Probe Technologies on how to survive the hospital

Renee Shenton
May 14 · 2 min read

The New York Times recently published an intriguing article on a new and emerging super-bug called Candida auris which is resistant to many commonly used anti-microbial drugs. C. auris is a fungus, a type of yeast. If C. auris enters the bloodstream, it can cause a life-threatening condition called sepsis. The mortality rate of C. auris bloodstream infections is approximately 50%. A subsequent NYTimes article detailed the tragic case of a woman in Chicago who contracted a C. auris bloodstream infection.

[….]

C. auris is a particular concern in the medical community because of its common resistance to anti-fungal drugs and its ability to develop drug-resistance while patients are being treated. Additionally, C. auris persists in the local hospital environment where infected patients are treated. For instance, it is difficult to eliminate from the beds, drapes, curtains, ceiling tiles, and other surfaces of hospital rooms, where it can potentially spread to other patients and healthcare workers.

Nuclease Probe Technologies has developed a rapid, logical, and systematic approach to development of assays that detect particular microbial pathogens. Proteins produced by bacteria and fungi like C. auris digest our proprietary detection probes which releases a fluorescent marker.

Read the full post here.

Breakout Labs

Fund within the Thiel Foundation that supports early stage companies as they transition radical scientific discoveries out of the lab and into the market.

Renee Shenton

Written by

Community Manager for Breakout Labs. Adventure Enthusiast at Camp Happy Trail.

Breakout Labs

Fund within the Thiel Foundation that supports early stage companies as they transition radical scientific discoveries out of the lab and into the market.